Articles tagged "Kidney transplantation"

2018 American Transplant Congress
Weight Changes before and after Kidney Donation
A. Bugeja,¹ S. Harris,² J. Ernst,¹ K. D. Burns,¹ G. Knoll,¹ E. G. Clark.¹
¹Medicine, The Ottawa Hospital, Ottawa, ON, Canada; ²Faculty of Science, University of Ottawa, Ottawa, ON, Canada.
IntroductionLiving kidney donors remain at low risk of end stage kidney disease but obese and overweight donors' risk is increased. We aimed to describe the…
2018 American Transplant Congress
Carfilzomib and Belatacept Reduces DSA and Prolongs Survival in a Highly Sensitized Rhesus Model of Kidney Transplantation
B. Ezekian, J. Kwun, P. Schroder, M. Manook, J. Yoon, M. Mulvihill, K. Freischlag, J. Cochran, K. Kroning, J. Yi, S. Knechtle.
Duke Transplant Center, Duke University Medical Center, Durham, NC.
Purpose:Sensitized kidney transplant (KT) recipients have poor access to transplantation and inferior outcomes when transplanted. Conventional methods of desensitization remove donor specific antibody (DSA) temporarily,…
2018 American Transplant Congress
The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients
F. Vincenti, J. Cruzado, S. Mulgaonkar, V. Garcia, D. Kuypers, M. Buchler, F. Citterio, U. Huynh-Do, W-.L. Luo, P. Bernhardt, C. Sommerer.
TRANSFORM Study Group, Novartis Pharma AG, Basel, Switzerland.
Purpose: Post-transplant (Tx) bacterial and viral infections are known to affect graft and patient survival. Accumulating evidence supports the protective effect of everolimus (EVR) against…
2018 American Transplant Congress
Endothelin-1 Type A Receptor Antibodies Are Associated with Elevated Il-8, Arteritis and Decline in Renal Function in Pediatric Renal Transplant Recipients
M. Pearl,¹ J. Grotts,¹ M. Rossetti,¹ Q. Zhang,¹ P. Weng,¹ E. Reed,¹ E. Tsai Chambers.²
¹University of California, Los Angeles, Los Angeles, CA; ²Duke University, Durham, NC.
Background: We have recently shown that the non-HLA antibody, AT1R-Ab, is prevalent and associated with poor outcomes in pediatric kidney transplant recipients (KTRs). The prevalence…
2018 American Transplant Congress
Immunophenotype of Cells Infiltrating the Graft Explains the Benefits of Belatacept
J. Furuzawa-Carballeda,¹ N. Uribe-Uribe,² G. Mondragon-Ramirez,⁴ J. Arreola-Guerra,⁵ R. Reyes-Acevedo,⁵ M. Vilatoba,³ R. Chavez-Fernandez,¹ F. Lopez-Verdugo,¹ A. Lopez-Toledo,⁴ G. Mondragon-Salgado,⁴ J. Alberu.³
¹Immunology, Inst. Nal. C. Medicas y Nutricion SZ, Mexico City, Mexico; ²Pathology, Inst. Nal. C. Medicas y Nutricion SZ, Mexico City, Mexico; ³Transplantation, Inst. Nal. C. Medicas y Nutricion SZ, Mexico City, Mexico; ⁴Inst Mex de Trasplantes, Cuernavaca, Mexico; ⁵Transplantation, C. Hospital Miguel Hidalgo, Aguascalientes, Mexico.
Previously, we found greater amounts of FoxP3 cells and lower amounts of CD4+/IL-17A+ and senescent cells in belatacept (Bela) patients compared to patients under cyclosporine…
2018 American Transplant Congress
Longitudinal Analysis of Community Respiratory Virus Infection in Kidney Transplant Recipients
O. Beaird, K. Phonphok, S. Chandrasekaran, O. Garner, S. Bunnapradist, J. Schaenman.
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Purpose: Community respiratory viruses (CRVs) cause significant morbidity and mortality in solid organ transplant recipients, but little is known about the epidemiology of CRV infections…
2018 American Transplant Congress
CMV-Specific Cell-Mediated Immunity after Valgancyclovir Prophylaxis Predicts Late Onset CMV Infection in Kidney Transplant Patients
M. Jarque,¹ E. Crespo,¹ E. Melilli,² A. Manonelles,² N. Montero,² S. Luque,¹ J. Cruzado,^1,2 J. Grinyo,^1,2 O. Bestard.^1,2
¹Experimental Nephrology Laboratory, IDIBELL, Barcelona, Spain; ²Nephrology Department, Bellvitge University Hospital, Barcelona, Spain.
Background: There is currently no means to predict late-onset CMV infection after a long course of post-transplant Valgancyclovir prophylaxis therapy and its development still negatively…
2018 American Transplant Congress
Thymoglobulin Induction Decreases Risk of Death in HLA-Sensitized Kidney Recipients
C. Loheac, O. Aubert, M. Assayag, D. Viglietti, C. Lefaucheur, A. Loupy.
Paris Translational Research Center for Organ Transplantation, Paris, France.
Anti-thymocyte globulin (ATG) is currently the preferential induction treatment in kidney recipients at high risk for allograft rejection. However, no study has evaluated the benefits…
2018 American Transplant Congress
BK Polyomavirus (BKPyV)-Specific T Cells as a Diagnostic and Prognostic Marker for BKPyV-Infections after Pediatric Kidney Transplantation
T. Ahlenstiel-Grunow,¹ M. Sester,² U. Sester,³ L. Pape.¹
¹Pediatric Nephrology, Hannover Medical School, Hannover, Germany; ²Transplant and Infection Immunology, Saarland University, Homburg, Germany; ³Internal Medicine IV, Saarland University, Homburg, Germany.
After kidney transplantation (KTx) immunosuppressive therapy causes an impaired cellular immune defense resulting in an increased risk of BKPyV-nephropathy (BKPyVAN). Prognostic markers for the outcome…
2018 American Transplant Congress
RNA Expression Profiling of Renal Allografts in a Non-Human Primate Identifies Inflammation as a Risk Factor in Chronic Antibody Mediated Rejection
R. Smith,¹ B. Adam,² A. Rosales,¹ M. Matsunami,³ T. Oura,³ B. Cosimi,³ T. Kawai,³ M. Mengel,² R. Colviin.¹
¹Pathology, Massachusetts General Hospital, Boston, MA; ²Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ³Surgery, Massachusetts General Hospital, Boston, MA.
IntroductionChronic alloantibody mediated rejection (CAMR) is a major risk factor in renal allografts. Some inflammation is commonly identified within CAMR, though mostly low grade, and…